Cargando…

mTOR inhibition rescues osteopenia in mice with systemic sclerosis

Fibrillin-1 (FBN1) deficiency-induced systemic sclerosis is attributed to elevation of interleukin-4 (IL4) and TGF-β, but the mechanism underlying FBN1 deficiency–associated osteopenia is not fully understood. We show that bone marrow mesenchymal stem cells (BMMSCs) from FBN1-deficient (Fbn1(+/−)) m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chider, Akiyama, Kentaro, Wang, Dandan, Xu, Xingtian, Li, Bei, Moshaverinia, Alireza, Brombacher, Frank, Sun, Lingyun, Shi, Songtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291526/ https://www.ncbi.nlm.nih.gov/pubmed/25534817 http://dx.doi.org/10.1084/jem.20140643

Ejemplares similares

Pluronic F-127 hydrogel as a promising scaffold for encapsulation of dental-derived mesenchymal stem cells
por: Diniz, Ivana M. A., et al.
Publicado: (2015)

Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression
por: Chen, Chider, et al.
Publicado: (2014)

mTOR Signaling in the Regulation of CD4+ T Cell Subsets in Periodontal Diseases
por: Jiang, Qian, et al.
Publicado: (2022)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis
por: Ramamurthy, Aishwarya, et al.
Publicado: (2023)

Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice
por: Xing, Xiaoliang, et al.
Publicado: (2019)

Mesenchymal Stem Cell-Based Tissue Regeneration is Governed by Recipient T Lymphocyte via IFN-γ and TNF-α
por: Liu, Yi, et al.
Publicado: (2011)

Is mTOR inhibition a systemic treatment for tuberous sclerosis?
por: Moavero, Romina, et al.
Publicado: (2013)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition
por: MacDonald, Elizabeth M., et al.
Publicado: (2014)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage
por: Panieri, Emiliano, et al.
Publicado: (2010)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
por: Polchi, Alice, et al.
Publicado: (2018)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
por: Węsierska-Gądek, Józefa
Publicado: (2010)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Genetically Determined Levels of mTOR-Dependent Circulating Proteins and Risk of Multiple Sclerosis
por: Zhang, Yao-Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_afssj9mb8sikid2o1ktmirmvi5